Single variable domains against notch pathway members
US8557965B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 7, 2009 |
| Grant date | Oct 15, 2013 |
| Priority date | — |
| Expiry date | Aug 25, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to amino acid sequences (also referred to herein as “single variable domain(s) of the invention”. “Nanobody™ of the invention” or “Nanobodies™ of the invention”, ilpolypeptide(s) of the invention”) that are directed against (as defined herein) members of the Notch signalling pathway such as the four mammalian members of the Notch Receptors (Notch-1, Notch-2, Notch-3, Notch-4, hereinafter also “Notch Receptors”) and the five mammalian members of the Notch Ligands (the Delta-like family with “DLL1”, “DLL3”, “DLL4” wherein “DLL” stands for Delta-like ligand; the Jagged family with “Jagged-1”, “Jagged-2”, hereinafter also “Notch Ligands”), as well as to constructs that comprise or essentially consist of one or more such single variable domain(s) (also referred to herein as “construct of the invention” and “constructs of the invention”, “Nanobody™ of the invention” or “Nanobodies™ of the invention”, respectively). In particular, this invention relates to Notch pathway interfering single variable domains down- or up-regulating Notch signaling (also referred to herein “Notch-antagonists” or “Notch-agonists”).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.